Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis b vaccine (recombinant) (GC Biopharma Corp)
- Development stage
- Approved
- Lead developer
- GC Biopharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Hepavax-Gene is a recombinant hepatitis B vaccine containing the hepatitis B surface antigen (HBsAg). It is produced using recombinant DNA technology, typically expressed in yeast systems such as *Hansenula polymorpha*. The vaccine consists of purified HBsAg adsorbed onto aluminum hydroxide, which serves as an adjuvant to enhance the host's immune response. It is indicated for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV). Clinical research, including studies by Chiang Mai University, has explored optimized dosing strategies for Hepavax-Gene in immunocompromised populations, such as HIV-infected adults, to improve seroconversion rates through intensive or double-dose regimens. A thiomersal-free version, Hepavax-Gene TF, is also available.
- Brand names
- Hepavax-GeneHepavax-Gene TF
- Other names
- recombinant hepatitis B surface antigen vaccineHBsAg vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)T-cell receptor recognizing Hepatitis B surface antigen-derived peptides presented by MHC class II
Beyond the preview
Go deeper on hepatitis b vaccine (recombinant) (GC Biopharma Corp).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis b vaccine (recombinant) (GC Biopharma Corp).